NASDAQ:LENZ LENZ Therapeutics Q2 2025 Earnings Results & Report $3.82 -0.31 (-7.51%) Closing price 04:00 PM EasternExtended Trading$3.87 +0.05 (+1.31%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. LENZ Therapeutics beat analyst earnings expectations and met on revenue in its Q2 2025 results, released July 30, 2025. The company reported EPS of -$0.53 versus the -$0.58 consensus estimate, while revenue of $5 million matched the $5 million estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateJuly 30, 2025TimeBefore Market OpensConference Call8:00 AM ET LENZ Therapeutics EPS ResultsActual EPS-$0.53Consensus EPS -$0.58Beat/MissBeat by +$0.05One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersLENZ Therapeutics Revenue ResultsActual Revenue$5 millionExpected Revenue$5 millionBeat/MissMet ExpectationsYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) LENZ Therapeutics Q2 2025 Earnings FAQ Did LENZ Therapeutics beat earnings estimates for Q2 2025? LENZ Therapeutics (NASDAQ:LENZ) reported earnings of -$0.53 per share for Q2 2025, beating the consensus estimate of -$0.58. The report was announced on Wednesday, July 30, 2025. What was LENZ Therapeutics' revenue for Q2 2025? LENZ Therapeutics reported revenue of $5 million for Q2 2025, against a consensus estimate of $5 million. LENZ Therapeutics Earnings HeadlinesLENZ Therapeutics: Don't Be Tempted With This Value TrapNovember 13 at 5:45 PM | seekingalpha.comLENZ Therapeutics, Inc. (NASDAQ:LENZ) Stock Has Consensus Target Price of $14.75November 12, 2026 | americanbankingnews.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.November 16 at 1:00 AM | Profits Run (Ad)HC Wainwright Has Optimistic Opinion of LENZ FY2026 EarningsNovember 5, 2026 | americanbankingnews.comLENZ Therapeutics (LENZ) Stock Fair Value Moves Lower As Analysts Split On VIZZNovember 4, 2026 | finance.yahoo.comLENZ Therapeutics consensus price target decreased by 25% to $15.30November 3, 2026 | msn.comSee More LENZ Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like LENZ Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on LENZ Therapeutics and other key companies, straight to your email. Email Address About LENZ TherapeuticsLENZ Therapeutics (NASDAQ:LENZ) is a biopharmaceutical company focused on developing treatments for presbyopia, the age-related difficulty focusing on nearby objects. Its lead product, VIZZ (aceclidine ophthalmic solution), is a prescription eye drop approved in the United States for treating presbyopia in adults. VIZZ is designed to improve near vision by constricting the pupil, which can increase depth of focus. The company’s work centers on developing and commercializing this topical, non-invasive treatment as an alternative to corrective eyewear for people with presbyopia. LENZ became a publicly traded company in 2024 following a merger with Graphite Bio. Its business is focused on the U.S. market for presbyopia treatments.View LENZ Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/133 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCould Big Buybacks Be the Next Catalyst for These 3 AI Stocks?Cerebras Q3 Results: How Much More Proof Does Wall Street Need? Upcoming Earnings Walt Disney (11/17/2026)Home Depot (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.